UK generic move could cost brand firms £17 million a year
This article was originally published in Scrip
Executive Summary
Branded pharmaceutical companies could lose a total of £17 million in profits annually if generic substitution is introduced in the UK. The move could also affect industry investment in R&D in the UK, but any such impact is likely to be limited, says the Department of Health, which has just launched a consultation on the proposal.